信立泰：SAL0139片临床试验申请获得受理

Core Viewpoint - The company, Xinlitai, has received approval from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0139 tablets [1] Group 1 - The company announced on the evening of September 5 that it has received a notice of acceptance for its clinical trial application [1] - The drug SAL0139 is developed independently by the company [1]